Axsome Therapeutics, Inc. (AXSM)
AXSMNASDAQ-GMBiotechnology: Pharmaceutical Preparations
$133.96
+1.59 (+1.20%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $7.05bn
- P/E
- –
- EPS, last 4 quarters
- $-3.21
- Dividend yield
- –
- Day range
- –
- 52-week range
- $123.00 to $260.19
- Average volume
- 868.4k
- Previous close
- $132.37
Analysts
19 coveringBuy18 buy, 1 hold, 0 sell
Targets a year out average $260.42, +94.4% from here
Earnings
next estimate $-0.0600Next report
Dec 2025
-1.4%
Mar 2026
-48.2%
Jun 2026
0.0%
Sep 2026
+63.8%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $196.00m | $191.20m | $218.38m | $259.69m |
| Gross profit | $183.67m | $176.48m | $204.81m | $241.89m |
| Operating income | -$26.96m | -$63.36m | -$49.65m | -$11.07m |
| Net income | -$28.56m | -$64.54m | -$51.31m | -$12.88m |
Last four quarters: revenue $865.27m, margin -18.2%, free cash flow -$82.61m
News
8 latest- Axsome Therapeutics vs. BioNTech: Which Healthcare Stock Is a Better Buy for 2027?The Motley Fool · 4 days ago
- Axsome: 3 Key Takeaways for Long-Term InvestorsThe Motley Fool · 5 days ago
- Axsome (AXSM) Q3 2026 Earnings Call TranscriptThe Motley Fool · Nov 2, 2026
- What Axsome Therapeutics (AXSM) Said on Its Q3 Earnings CallMarketBeat · Nov 2, 2026
- Axsome Therapeutics Q3 Sales Rise Across Key Brands; Pipeline Milestones Set For 2027 RTTNews · Nov 2, 2026
- Axsome (AXSM) Reports Q3 Earnings: What Key Metrics Have to SayZacks · Nov 2, 2026
- Axsome Therapeutics (AXSM) Reports Q3 Loss, Tops Revenue EstimatesZacks · Nov 2, 2026
- Could Axsome Therapeutics Turn $5,000 Into $50,000 by 2035?The Motley Fool · Oct 29, 2026
The company
Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, agitation associated with dementia due to Alzheimer's disease, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, as well as multiple novel product candidates addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain's biggest problems so patients and their loved ones can flourish.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- axsome.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.